Once-daily valacyclovir to reduce the risk of transmission of genital herpes*

@article{Corey2004OncedailyVT,
  title={Once-daily valacyclovir to reduce the risk of transmission of genital herpes*},
  author={Lawrence Corey and Anna Wald and Raj Patel and Stephen L. Sacks and Stephen K. Tyring and Terri J Warren and John M. Douglas and Jorma Paavonen and Rhoda Ashley Morrow and Karl R. Beutner and Leonid Stratchounsky and Gregory J. Mertz and Oliver N Keene and Helen A. Watson and Dereck R. Tait and Mauricio Vargas-Cortes},
  journal={Obstetrics \& Gynecology},
  year={2004},
  volume={103},
  pages={797}
}
BACKGROUND Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV. METHODS We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic genital HSV-2 and one susceptible to HSV-2. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The… Expand
Reducing the transmission of genital herpes
  • S. Barton
  • Medicine
  • BMJ : British Medical Journal
  • 2005
TLDR
A recently published study was undertaken in 1484 heterosexual, immunocompetent couples to determine if daily valaciclovir could reduce the sexual transmission of genital herpes. Expand
Does Frequency of Genital Herpes Recurrences Predict Risk of Transmission? Further Analysis of the Valacyclovir Transmission Study
TLDR
Clinical assessment of HSV-2 disease severity as defined by the frequency of genital herpes recurrences does not predict the risk of transmission to sexual partners, and frequency of recurrence is not helpful in identifying persons who are most likely to transmit HSv-2. Expand
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
TLDR
In placebo-controlled trials, there was a low quality evidence that the risk of having at least one clinical recurrence was reduced with acyclovir, and in parallel-group trials by daily dose, no clear evidence was found of a dose-response relationship for any drug. Expand
Famciclovir Reduces Viral Mucosal Shedding in HSV-Seropositive Persons
TLDR
Famciclovir therapy decreases genital HSV shedding in HSV-seropositive persons, especially those with a history of genital herpes, and antiviral drugs may have varying effects on symptomatic and asymptomatic viral shedding, depending on the clinical history of the disease. Expand
Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
TLDR
It is demonstrated that 1 g/d of valacyclovir administered for 60 days was generally well tolerated and was an effective suppressive therapy that significantly reduced total (clinical and subclinical) HSV-2 shedding compared with placebo in immunocompetent patients diagnosed as having recurrent HSv-2 genital herpes. Expand
Utility of episodic acyclovir therapy for HSV-2 in Africa.
TLDR
A randomized trial of episodic acyclovir therapy among 88 HIV-1 seronegative, HSV-2 seropositive African women with recurrent genital herpes concluded that diminished virologic response to acyClovir among African women did not explain the failure of HSv-2 suppressive therapy to prevent HIV acquisition and has potential when included as part of first-line syndromic management of GUD. Expand
Famciclovir for the treatment of recurrent genital herpes: a clinical and pharmacological perspective
TLDR
Famciclovir, a synthetic acyclic guanine derivative, is the prodrug of pencic Lovir, which demonstrates in vitro antiviral activity against various types of herpes virus, including herpes simplex virus-2, and is well tolerated, with an adverse events profile similar to placebo. Expand
Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery: A Randomized Clinical Trial
TLDR
Valacyclovir suppression after 36 weeks of gestation significantly reduces HSV shedding and recurrent genital herpes requiring cesarean delivery. Expand
Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
TLDR
Administration of valacyclovir beginning at 36 weeks' gestation to women with a history of recurrent genital HSV reduced the number of women with subsequent clinical HSV recurrences. Expand
Genital herpes.
TLDR
Since clinical diagnosis is neither sensitive nor specific, virological and type-specific serological tests should be used routinely and oral antiviral drugs for HSV infections are safe and effective and can be used both to treat episodes and to prevent recurrences. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.
TLDR
It is demonstrated that once daily valaciclovir (500 mg), is highly effective and well tolerated for the suppression of recurrent genital HSV infection. Expand
Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
BACKGROUND An effective prophylactic vaccine would help control the spread of genital herpes. METHODS We conducted two double-blind, randomized trials of a herpes simplex virus type 2 (HSV-2)Expand
Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.
TLDR
Analysis of data from a randomized, double-blind, placebo-controlled trial of an ineffective candidate HSV-2 vaccine suggests that identification of discordant couples can reduce transmission of HSv-2, especially for heterosexual couples in which the male partner has HSV -2 infection. Expand
Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.
TLDR
HSV-2 shedding in the genital mucosa occurs much more frequently than previously appreciated and likely plays a role in the epidemic spread of genital herpes worldwide. Expand
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.
TLDR
Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes. Expand
Frequency of Acquisition of First‐episode Genital Infection with Herpes Simplex Virus from Symptomatic and Asymptomatic Source Contacts
TLDR
Efforts to identify individuals with undiagnosed genital herpes and to instruct these individuals concerning the risk of disease transmission in the presence of lesions are needed if the rate of transmission is to be decreased; however, methods designed to deerease the rates of transmission by asymptomatic individuals must also be evaluated. Expand
Recurrence Rates in Genital Herpes after Symptomatic First-Episode Infection
TLDR
The natural history of symptomatic recurrences in the complete population and in the subset of untreated patients is summarized. Expand
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
TLDR
Efficient and sustained protection from sexual acquisition of HSV-2 infection will require more than high titers of specific neutralizing antibodies, and protection against sexually transmitted viruses involving exposure over a prolonged period will require a higher degree of vaccine efficacy than that achieved in this study. Expand
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.
TLDR
Nearly 40 percent of newly acquired HSV-2 infections and nearly two thirds of new HSv-1 infections are symptomatic, and among sexually active adults, new genital HSVs type 1 and 2 infections are as common as new oropharyngeal HSV -1 infections. Expand
The association between genital ulcer disease and acquisition of HIV infection in homosexual men.
TLDR
It is suggested that genital ulcerative diseases are an important risk factor for the acquisition of HIV infection in homosexual men; measures directed at control of these diseases may reduce the transmission of HIV in this population. Expand
...
1
2
3
4
...